Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03692429
Title alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celyad Oncology SA

colon adenocarcinoma

rectum adenocarcinoma


Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin

Fluorouracil + Irinotecan + Leucovorin + NKR-2 cells

Age Groups: adult | senior
Covered Countries USA | BEL

Facility Status City State Zip Country Details
Moffit Cancer Center Not yet recruiting Tampa Florida 33612 United States Details
Institut Jules Bordet Recruiting Brussels 1000 Belgium Details
UZ Antwerpen Recruiting Edegem 2650 Belgium Details
UZ Leuven Recruiting Leuven 3000 Belgium Details
*Shaded cells indicate that there was no data available from for the field